title: The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
abstract: BACKGROUND
  The Mirasol Pathogen Reduction Technology system for platelets and plasma uses riboflavin and UV light to introduce irreparable lesions into nucleic acids thereby inhibiting pathogen and white blood cell replication and reducing the load of infectious pathogens. The aim of the present study was to evaluate low plasma buffy coat platelet concentrates obtained from the OrbiSac System and to examine the effects on the development of platelet storage lesion during storage in platelet additive solution.
  
  
  METHODS
  Twenty buffy coat platelet concentrates were generated by pooling five individual units using the OrbiSac System. Riboflavin was added during the final pooling step, and the units were exposed to UV light. The bag was removed after the target energy of 6.24 J/mL had been delivered and 150 mL of platelet additive solution were added prior to storage. Platelet quality was assessed by pH, swirl, CD62P expression, lactate dehydrogenase, lactate production and glucose consumption rates over 7 days of storage.
  
  
  RESULTS
  Buffy coat platelet concentrates generated on the OrbiSac contained an average 3.5 +/- 0.6 x 10(11) platelets at a concentration of 2976+/- 406 x 10(6)/mL. After addition of 150 mL platelet additive solution the storage concentration was 1043 +/- 148x 10(6)/mL. Values obtained for pH, lactate production and glucose consumption rates were all within the limits of previously established correlations between in vitro cell quality and in vivo performance of Pathogen Reduction Technology-treated platelets in plasma.
  
  
  CONCLUSIONS
  In vitro studies show that OrbiSac-derived platelets treated with the Mirasol Pathogen Reduction Technology system preserve adequate function, which would indicate acceptable in vitro viability.
authors.affiliation: Haematological department, Institute of Internal Medicine, University of Bergen, Norway.
authors.forename: Håkon
authors.initials: H
authors.lastname: Reikvam
authors.forename: Susanne
authors.initials: S
authors.lastname: Marschner
authors.forename: Torunn Oveland
authors.initials: TO
authors.lastname: Apelseth
authors.forename: Ray
authors.initials: R
authors.lastname: Goodrich
authors.forename: Tor
authors.initials: T
authors.lastname: Hervig
mesh_terms: D020811:Biomedical Technology; D058621:Blood Buffy Coat / Q000166:cytology*; D001792:Blood Platelets / Q000166:cytology*; D001793:Blood Preservation / Q000379:methods*; D002470:Cell Survival; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000096:biosynthesis; D019999:Pharmaceutical Solutions; D010976:Platelet Count; D012256:Riboflavin / Q000494:pharmacology; D014466:Ultraviolet Rays
chemical_list: D019999:Pharmaceutical Solutions; D019344:Lactic Acid; D005947:Glucose; D012256:Riboflavin